Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Buy
56
CDMO Quote, Financials, Valuation and Earnings
Last price:
$12.31
Seasonality move
:
76.3%
Day range:
$12.29 - $12.34
52-week range:
$5.65 - $12.48
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
5.21x
P/B ratio:
17.59x
Volume:
1M
Avg. volume:
2M
1-year change:
98.71%
Market cap:
$788M
Revenue:
$139.9M
EPS (TTM):
-$2.39
Analysts' Opinion
-
Consensus RatingAvid Bioservices has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Avid Bioservices has an estimated upside of 4.51% from its current price of $12.32.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $12.32.
Fair Value
-
According to the consensus of 0 analysts, Avid Bioservices has 4.51% upside to fair value with a price target of -- per share.
CDMO vs. S&P 500
-
Over the past 5 trading days, Avid Bioservices has overperformed the S&P 500 by 1.86% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Avid Bioservices does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Avid Bioservices has grown year-over-year revenues for 3 quarters straight. In the most recent quarter Avid Bioservices reported revenues of $33.5M.
Earnings Growth
-
Avid Bioservices earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Avid Bioservices reported earnings per share of -$0.27.
Enterprise value:
908.8M
EV / Invested capital:
4.57x
Price / LTM sales:
5.21x
EV / EBIT:
--
EV / Revenue:
6.04x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
-93.87x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$11.6M
Return On Assets:
-39.92%
Net Income Margin (TTM):
-101.07%
Return On Equity:
-143.94%
Return On Invested Capital:
-59.75%
Operating Margin:
-37.73%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-10-31 | 2023-10-31 | 2024-10-31 | 2023-10-31 | 2024-10-31 | |
| Income Statement | ||||||
| Revenue | $134.2M | $140.9M | $150.4M | $25.4M | $33.5M | |
| Gross Profit | $29.3M | $17.7M | $11.6M | -$4.7M | -$2M | |
| Operating Income | $4.4M | -$9.8M | -$20.4M | -$11.2M | -$12.6M | |
| EBITDA | $10.2M | $604K | -$14.3M | -$8.3M | -$10.2M | |
| Diluted EPS | $1.70 | -$0.19 | -$2.39 | -$0.15 | -$0.27 | |
| Period Ending | 2020-10-31 | 2021-10-31 | 2022-10-31 | 2023-10-31 | 2024-10-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $63.1M | $206.9M | $145.9M | $104.2M | $96.5M | |
| Total Assets | $113.6M | $301.6M | $441.9M | $454.6M | $323.5M | |
| Current Liabilities | $43.7M | $69.5M | $82.4M | $76.9M | $74.2M | |
| Total Liabilities | $64.2M | $250.5M | $260.7M | $271M | $278.7M | |
| Total Equity | $49.4M | $51.1M | $181.2M | $183.7M | $44.8M | |
| Total Debt | -- | $139.1M | $140.1M | $141.2M | $154.1M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-10-31 | 2023-10-31 | 2024-10-31 | 2023-10-31 | 2024-10-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$3.1M | $2.2M | $5.3M | $6.2M | $4M | |
| Cash From Investing | -$85.9M | -$58.2M | -$14.9M | -$7.5M | -$3.4M | |
| Cash From Financing | $2.6M | $9.7M | $11.7M | $7.4M | -$513K | |
| Free Cash Flow | -$89M | -$55.9M | -$9.7M | -$1.2M | $547K | |
CDMO
Sector
Market Cap
$788M
$44.6M
Price % of 52-Week High
98.72%
45.71%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.68%
1-Year Price Total Return
98.71%
-29.09%
Beta (5-Year)
1.444
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$12.32
200-day SMA
Buy
Level
$9.40
Bollinger Bands (100)
Buy
Level
10.14 - 12.04
Chaikin Money Flow
Sell
Level
-388.4M
20-day SMA
Buy
Level
$12.31
Relative Strength Index (RSI14)
Buy
Level
63.51
ADX Line
Sell
Level
7.14
Williams %R
Neutral
Level
-23.6364
50-day SMA
Buy
Level
$11.50
MACD (12, 26)
Buy
Level
0.18
25-day Aroon Oscillator
Buy
Level
32
On Balance Volume
Neutral
Level
361.1M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-1.0098)
Sell
CA Score
(Annual)
Level (-1.4235)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (3.3762)
Buy
Piotroski F Score
(Annual)
Level (5)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Avid Bioservices Inc is a clinical-stage biopharmaceutical company focused on the development and Current Good Manufacturing Practices (CGMP) of biopharmaceutical products derived from mammalian cell culture. Its business is organized into one reportable operating segment which is contract manufacturing and development services segment. Its services include clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. The company also provides a variety of process development services including cell line development, upstream and downstream development and optimization, analytical method development, testing and characterization.
Stock Forecast FAQ
In the current month, CDMO has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CDMO average analyst price target in the past 3 months is --.
-
Where Will Avid Bioservices Stock Be In 1 Year?
According to analysts, the consensus estimate is that Avid Bioservices share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Avid Bioservices?
Analysts are divided on their view about Avid Bioservices share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Avid Bioservices is a Sell and believe this share price will drop from its current level to --.
-
What Is Avid Bioservices's Price Target?
The price target for Avid Bioservices over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CDMO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Avid Bioservices is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CDMO?
You can purchase shares of Avid Bioservices via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Avid Bioservices shares.
-
What Is The Avid Bioservices Share Price Today?
Avid Bioservices was last trading at $12.31 per share. This represents the most recent stock quote for Avid Bioservices. Yesterday, Avid Bioservices closed at $12.32 per share.
-
How To Buy Avid Bioservices Stock Online?
In order to purchase Avid Bioservices stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
